Edition:
India

Claris Lifesciences Ltd (CLAI.BO)

CLAI.BO on Bombay Stock Exchange

353.00INR
23 Jul 2017
Change (% chg)

Rs-7.00 (-1.94%)
Prev Close
Rs360.00
Open
Rs358.00
Day's High
Rs362.70
Day's Low
Rs353.00
Volume
24,122
Avg. Vol
82,681
52-wk High
Rs430.10
52-wk Low
Rs210.00

CLAI.BO

Chart for CLAI.BO

About

Claris Lifesciences Limited is a holding company. The Company is engaged in manufacturing of drugs and pharmaceutical products. The Company's geographical segments are India and Outside India. The Company's subsidiary, Claris Injectables Limited, is engaged in specialty Injectables business. The Company manufactures and markets... (more)

Overall

Beta: 0.98
Market Cap(Mil.): Rs19,325.17
Shares Outstanding(Mil.): 54.57
Dividend: 2.00
Yield (%): 0.56

Financials

  CLAI.BO Industry Sector
P/E (TTM): -- 13.56 17.15
EPS (TTM): -2.17 -- --
ROI: -0.44 -7.26 -5.60
ROE: -1.04 -6.80 -4.89

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

21 Jul 2017

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON, July 20 Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

21 Jul 2017

BRIEF-Claris Lifesciences underwent a successful USFDA Pharmacovigilance (PV) audit

* Says underwent a successful USFDA Pharmacovigilance (PV) audit from Monday 29th may to Wednesday 31st May with no observation

01 Jun 2017

BRIEF-Claris Lifesciences approves sale of shares of Otsuka Pharmaceutical India for $20 mln

* Says approved sale of shares of Otsuka Pharmaceutical India to Otsuka Pharmaceutical Factory for $20 million Source text for Eikon: Further company coverage:

08 May 2017

BRIEF-Claris Lifesciences gets members' nod for sale, transfer of injectable business

* Gets members' nod for sale and transfer of injectable business of co by way of sale of subsidiary companies Source text: http://bit.ly/2kD0uPT Further company coverage:

20 Feb 2017

BRIEF-Claris Lifesciences posts consol Dec qtr profit

* Consol dec quarter total income from operations 86.3 million rupees

14 Feb 2017

Earnings vs. Estimates